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Introduction
Prevention is the only chance to reduce morbidity and 
mortality from myocardial infarction (MI), and current 
therapies cannot restore the lost cardiac muscle tissue. 
In addition, human heart has a very limited regenerating 
potential, and common strategies aimed at preventing MI 
events are not always effective (1). Moreover, the only 
cure for patients with advanced heart failure (HF) is heart 
transplantation (2). Therefore, it is necessary to develop 
innovative therapies to repair the damaged cardiac muscle 
and improve the quality of patients’ life. This goal could be 
reached by applying cell therapy, the essence of regenerative 
medicine, to coronary heart disease (CHD). So far, several 
preclinical and clinical studies have been pursuing this 
strategy, which implies the transplantation of autologous 
stem or progenitor cells into the damaged myocardium in 
order to restore the lost function.
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Unfortunately, clinical results are far from being 
satisfactory, because of the contrasting evidence about the 
benefits deriving from cell therapy in CHD. Indeed, even 
though some clinical trials report promising data, others do 
not show improvement in heart function after cell therapy. 
The only clear advantage reported in most of the clinical 
studies, is the reduction of the infarcted area and of non-
functional scarring tissue. This review provides a critical 
update on the clinical studies evaluating the efficacy of cell 
therapy applied to CHD.
Cell sources
The final  outcome of an ischemic damage to the 
myocardium is the formation of non-functional scar 
tissue. Therefore, modern approaches for MI are aimed at 
restoring the contractile function of infarcted myocardium. 
In particular, transplantation of stem and progenitor cells 
has been widely studied. Preclinical studies on small and 
large mammals have used different cell types, such as 
embryonic stem cells (ESCs), induced pluripotent stem 
cells (iPSCs), skeletal myoblasts (Sk-Mbs), adult bone 
marrow-derived mononuclear cells (BM-MNCs), adult 
bone marrow-derived mesenchymal cells (BM-MSCs), 
endothelial progenitor cells (EPCs), adipose-derived 
stem cells (Ad-SCs), adipose- derived MSCs (Ad-MSCs), 
umbilical cord blood mesenchymal stem cells (UC-MSCs), 
cardiac stem cells (CSCs), and pericytes (1,3,4). Some of 
these studies proved that cell therapy can favor the repair 
of the damaged heart tissue (5-7). However, due to several 
concerns about the therapeutic use of certain types of stem 
or precursor cells, recent clinical trials mainly focused on 
bone marrow-derived cells, and in particular on BM-MNCs 
and on BM-MSCs (Tables 1,2). Especially, BM-MSCs have 
been the preferred source for cell therapy in MI.
ESCs are totipotent cells isolated from the inner mass 
of the blastocyst. These cells can differentiate into all the 
cell types of an organism, but safety and ethical issues limit 
their use in clinical practice (32). iPSCs are pluripotent 
cells derived from genetically reprogrammed adult 
differentiated cells. These cells can generate cell types from 
all three germ layers including cardiomyocytes (CMs) (33). 
The use of iPSC-derived CMs (iPSC-CMs) for clinical 
practice is encouraged by the good results obtained in 
preclinical studies. Nonetheless, many issues, such as a 
standardized protocol for iPSC-CM generation, safety, 
expensiveness of the procedures remain still unsolved and 
the time for this type of cells to be introduced into clinical 
trials has yet to come (33).
Sk-Mbs derive from satellite cells, the quiescent skeletal 
muscle precursors residing under the basal membrane 
of muscle fibres (34). Sk-Mbs have been transplanted in 
ischemic myocardium to repair damaged tissue, but, due 
to the limited evidence regarding their efficacy and safety, 
their use in clinical trials is very restricted (35).
BM-MNCs comprise hematopoietic stem and progenitor 
cells, mesenchymal stromal cells, embryonic-like stem cells, 
multipotent adult progenitor cells, hemangioblasts, EPCs 
and tissue- committed stem cells (36). As for the delivery 
strategies, intramyocardial and intracoronary injections 
seem to be the preferred routes.
Given the large spectrum of cell types included 
in the population of BM-MNCs, clinical trials have 
been performed on specific subpopulations of BM-
MNCs, such as CD34+ and CD133+ cells. CD34+ and 
CD133+ are markers identifying also hematopoietic 
stem cells and endothelial progenitor cells which can 
differentiate into different types of adult blood and 
vascular cells.
BM-MSCs are multipotent cells that, under the 
appropriate stimuli, can differentiate into many tissues, such 
as bone, cartilage, fat, muscle, tendon.
EPCs are circulating cells derived from hematopoietic 
stem cells, that are capable of neovasculogenesis (37). These 
cells belong to the population of BM-derived cells and are 
characterized by specific surface markers such as CD31, 
CD34, and CD133 (38). Several studies demonstrated the 
potential benefits of EPCs in the treatment of MI, however 
very few are the clinical trials using selected EPCs for the 
treatment of patients with ischemic heart disease (39).
Adipose tissue contains mesenchymal stem cells 
(MSCs) and stem cells that can be used for cardiac repair 
strategies, as demonstrated in rodent models. In these 
studies, intramyocardial injection of adipose tissue-derived 
cells improved the recovery from MI (33). In addition, 
recent studies in humans have shown the beneficial effects 
of Ad-SCs transplantation in patients with ischemic 
cardiomyopathy (40). 
As far as umbilical cord-blood cells, a heterogeneous 
population of cells including hematopoietic stem cells, 
MSCs, and somatic stem cells, their use in CVD is very 
limited, although these cells have high proliferative capacity 
and can give rise to different cell types, among which 
cardiomyocytes (41).
CSCs are multipotent stem cells residing in the heart 
with self-renewal and cardiac repair properties (42,43). 
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These cells can be isolated also by spheroid clusters, named 
cardiospheres (CSpCs), which derive from primary culture 
of myocardial biopsies (44). Recently, the effectiveness of 
these cardiosphere-derived cells in post-ischemic heart 
failure has been challenged in studies on rats (45). 
Pericytes are cells of the microvascular wall, localised 
below the basal lamina underlying the endothelial cell layer 
of the microvessels. It has been demonstrated that these 
cells, in injured heart, can secrete different factors promoting 
angiogenesis, reducing fibrosis and apoptotic cell death in the 
damaged area (46-49). Moreover, intramyocardial injection 
of pericytes, together with cardiac stem cells, enhanced the 
repair of infarcted mouse hearts (50). Nevertheless, data on 
the beneficial effects of these cells on cardiac repair is limited, 
thus preventing their use in clinical trials.
Although there are many factors that limit the direct 
contribution of transplanted cells to myocardial repair 
process, such as cell engraftment, survival, proliferation, 
differentiation, and integration into the host tissue, benefits 
of this approach can last very long after the intervention, 
possibly because of the activation of endogenous repair 
process (1,51).
Delivery routes
In the clinical setting, intravenous, intracoronary, and 
intramyocardial injections are the three delivery strategies 
that have been used for cell transplantation. Each of them 
has advantages and drawbacks, thus an ultimate preferred 
procedure is not available yet. Nevertheless, in recent 
clinical trials, intracoronary and intramyocardial injections 
are the two most frequently used delivery routes for cell 
therapy (Table 1) (52).
Nowadays, in order to improve the benefits obtained 
with cell therapy, novel solutions are being investigated, 
such as those involving cell transplants supported by 
the simultaneous delivery of pro-repair drugs, synthetic 
scaffolds and growth factors (4).
Recent published clinical trials
Over the last 5 years, 20 clinical studies have been 
published on the use of cell therapy for CHD-derived 
conditions, such as acute myocardial infarction (AMI), 
CHD, left ventricular dysfunction (LVD), MI, angina 
(AG), HF, congestive heart failure (CHF) etc. (https://
clinicaltrials.gov/). Among these studies, 13 (65%) gave 
positive results, whereas 7 (35%) gave negative results 
regarding functional recovery of the heart. Nevertheless, 
cell therapy led to a reduction of scar size, even in cases 
where there was no clear recovery of cardiac function in 
terms of ejection fraction. As previously stated, there is 
not a defined preference for a single delivery route, but 
almost all the studies used intracoronary or intramyocardial 
injections. Regarding the source of cells, there is a wide 
consensus on bone marrow cells (BMCs), due to the ease 
of BMC isolation and culture, as well as the presence of 
different multipotent stem cells in bone marrow (BM) (36). 
In particular, clinical studies used either the heterogeneous 
population of BMCs, or different subpopulations of 
BMCs, such as BM-MNCs, BM-MSCs, BM-CD34+, 
BM-CD133+. The advantage of using the whole population 
of BMCs derives from its heterogeneity, given that it is still 
unknown what type of cell from the BM could be effective 
for cell therapy in CHD. On the other hand, the use of a 
very defined population of cells could be preferred to reach 
a standardized protocol.
The 13 clinical trials that yielded positive results 
are summarized below and reported in Table 1 .  In 
the NCT00962364, BMCs have been delivered by 
intracoronary injection in patients affected by chronic 
ischemic HF, resulting in an improvement of the 
cardiopulmonary exercise capacity. NCT00395811 trial 
showed that, at 12-month follow-up, the intramyocardial 
injection of BM-MNCs in patients with chronic MI during 
coronary artery bypass graft, led to a 5.5% improvement of 
the left ventricular ejection fraction (LVEF) and a significant 
improvement in contractility, without any variation in 
the infarct size. NCT00260338 trial demonstrated that 
intramyocardial delivery of BM-MSCs, in patients with CHD 
and refractory angina, improved exercise time, angina class, 
and weekly number of angina attacks. In NCT00474461, 
intracoronary infusion of autologous CSCs in patients with 
heart failure, after MI, improved left ventricular systolic 
function, reduced the infarct size and enhanced the viability 
of the myocardium. In NCT00587990, autologous MSCs 
have been injected intramyocardially in patients with 
chronic ischemic LVD secondary to MI, and undergoing 
coronary artery bypass grafting. As result, the treatment 
reduced the scar size and improved the perfusion and 
contractile properties of the injected myocardium areas. In 
NCT01291329 trial, 116 patients with acute ST-elevation 
MI (STEMI) were subjected to intracoronary injection of 
umbilical cord Wharton's jelly MSCs. As result, the treatment 
led, at 18 months, to an increase in myocardial viability and 
perfusion in the ischemic area, to an increase in LVEF and 
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a decrease in left ventricular end- systolic volumes (LVESV) 
and end-diastolic volumes. NCT00326989 trial showed 
that, in patients with HF, application of BMCs, after 
cardiac shock wave pretreatment, led to an increased LVEF, 
regional wall thickening, and reduction in the frequency 
of major adverse cardiac events. In NCT00644410 trial, 
intramyocardial injection of BM-MSCs in patients with 
congestive heart failure (CHF) caused a reduction in 
LVESV, and an improvement in LVEF, stroke volume, 
and myocardial mass. In NCT00810238 trial, BM-MSCs 
were differentiated into the cardiac lineage and injected 
intramyocardially in patients with chronic heart failure. 
As result, LVESV was reduced, and LVEF, 6-min walk 
distance, composite clinical score, physical performance, 
and event-free survival were improved. NCT01350310 trial 
demonstrated that transendocardial (TEC) administration 
of CD34+ cells in patients with ischemic cardiomyopathy 
led to an improvement in LVEF, an increase in 6-minute 
walk distance and a decrease in plasma concentration of the 
N-terminal pro B-type natriuretic peptide. In another trial 
with CD34+ cells (NCT01508910), intramyocardial injection 
of autologous cells in patients with refractory angina led to 
an improvement in total exercise time at 12 months and a 
reduced frequency of angina. In NCT02425358 trial, BM-
MNCs were delivered into the coronary arteries of MI patients 
with ST-elevation, who underwent percutaneous coronary 
intervention. In the first 7 days following percutaneous 
coronary intervention, cell therapy increased LVEF, decreased 
LVESV, and improved myocardial perfusion. Intracoronary 
injection of BM-MNCs in MI patients enrolled in the clinical 
trial NCT01234181 showed improvement in left ventricular 
end-diastolic volume (LVEDV) and LVESV at 6 and 
12 months. On the contrary, no enhancement was recorded in 
the LVEF.
In contrast with the previously cited clinical trials, 
seven published studies presented negative results for the 
use of cell therapy in ischemia-derived MI conditions: 
NCT00684021,  NCT00418418,  NCT00462774, 
NCT00984178,  NCT00355186,  NCT00765453, 
NCT00824005 (Table 1). These studies transplanted mainly 
BMCs either by intracoronary or intramyocardial delivery 
routes, and were applied mostly to patients affected by 
ischemic cardiomyopathies.
Ongoing clinical trials
Interestingly, the ongoing clinical trials (Table 2), adopt the 
same delivery routes which have been used in the recently 
published studies, that is intramyocardial and intracoronary 
injections. On the contrary, cell type and sources that have 
been used in these more recent studies are clearly different 
from the past. In fact, many running clinical trials are based 
on the use of BMCs, but a significant percentage of studies 
(28%) utilizes different cell types and sources, such as 
cardiac stem cells, cardiac progenitor cells, adipose-derived 
stem cells and MSCs derived from umbilical cord blood. 
The clinical trial NCT01458405 is based on the injection 
of allogeneic cardiosphere-derived cells (CAP-1002) in 
the coronary artery of MI patients. This study is aimed at 
verifying the safeness and effectiveness of the procedure, as 
measured by the size of the infarcted area. Intracoronary 
administration of allogeneic CSCs is the therapeutic 
strategy to treat patients with STEMI in NCT02439398 
trial. Three clinical trials are based on the use of UC-MSCs: 
NCT02666391, NCT02323477 and NCT03180450. The 
study NCT02666391 is assessing the safety and efficacy of 
the intracoronary injection of UC-MSCs in patients with 
ischemic heart diseases; the clinical trial NCT02323477 
is evaluating the efficacy of intramyocardial injection 
of UC-MSCs in patients with MI; in the clinical trial 
NCT03180450, allogeneic umbilical cord mesenchymal 
stem cells will be transplanted intravenously in patients with 
heart failure.
As for the use of AdSCs for the treatment of patients 
with LVEF ≤45% and heart failure, there are two clinical 
trials: NCT02673164 and NCT03092284. In these studies, 
the regenerative potential of intramyocardial injection of 
AdSCs will be evaluated. As already stated, the choice of cell 
type and source is of primary importance for the outcome 
of any cell-based strategy, as also highlighted by Cogle and 
collaborators, who studied the cellular composition of BM 
in patients with ischemic heart disease and severe LVD (53). 
Therefore, further knowledge is needed, but the enrichment 
of this research field with new factors and methods could 
push forward the use of cell therapy in CVD.
Novel strategies for cardiac repair
Given the limited efficacy of current cell therapies for 
MI, several different approaches are being investigated 
(Figure 1 ) .  As an example,  the group of Wai and 
collaborators has recently studied the role of follistatin-like-
protein 1 (FSTL1) in the activation of vascular remodeling 
and cardiomyocyte proliferation (54). Based on the evidence 
that cardiac FSTL1 expression is lost upon MI, authors 
hypothesized that the recovery of the myocardial activity 
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of FSTL1 would activate cardiomyocyte proliferation, thus 
restoring the function of the damaged heart (54). Indeed, 
transplantation of collagen patches loaded with human 
FSTL1 to the epicardial surface of mouse infarcted hearts 
increased the formation of new vessels, the number of 
dividing cardiomyocytes and partially restored myocardial 
functions. This evidence highlights the potential of 
biomaterial-based strategies to treat patients affected by 
MI. In MI mice, the subcutaneous inguinal injection of 
tolerogenic dendritic cells (bone marrow-derived dendritic 
cells treated with tumor necrosis factor-α and cardiac 
lysate from MI mice) improved wound remodeling, 
left ventricular systolic function and survival (55). Very 
recently, the combination of genetic engineering with cell 
therapy has led to an improvement in the treatment of 
MI. Indeed, in rat models of MI, both the transplantation 
Table 1 Published studies on coronary heart disease 
NIH registration 
number 
Study type 
No. of treated 
patients 
Cell type Condition Delivery route Year Reference 
NCT00260338 Non-randomized 31 BM-MSCs CHD, AG IM 2013 (8)
NCT00326989 Randomized, controlled, blind 100 BM-MNCs CHF IC 2013 (9)
NCT00355186 Randomized, controlled 200 BMCs AMI IC 2013,2016 (10,11)
NCT00395811 Randomized, controlled 50 BM-MSCs CHF IM 2013 (12)
NCT00418418 Randomized, controlled, blind 60 BM-MNCs HF, MI, CHD IM 2014 (13)
NCT00462774 Randomized, controlled, blind 60 CD133+ cells CHD, CHF, MI IM 2014 (14)
NCT00474461 Randomized, controlled 33 CSCs CAD, CHF IC 2012 (15,16)
NCT00587990 Randomized 9 MSCs CILVD IM 2014 (17)
NCT00644410 Randomized, controlled, blind 60 BM-MSCs CHF IM 2015 (18)
NCT00684021 Randomized, controlled, blind 120 BM-MNCs LVD IC 2011, 2014, 
2015
(19-21)
NCT00765453 Randomized, controlled, blind 100 BM-SCs AMI IC 2016 (22)
NCT00810238 Randomized, controlled, blind 240 BM-MSCCs HF TEC 2013 (23)
NCT00824005 Randomized, controlled, blind 92 BM-MNCs CIHD, LVD, AG, 
ICP
IM 2012 (24)
NCT00962364 Randomized 124 BMCs CIHF IC 2013 (25)
NCT00984178 Randomized, controlled, blind 120 BM-MNCs +/− 
G-CSF
AMI IC 2015 (26)
NCT01234181 Randomized, controlled 100 BM-MNCs MI, AMI IC 2015 (27)
NCT01291329 Randomized, controlled, blind 160 WJ-MSCs MI IC 2015 (28)
NCT01350310 Randomized, controlled, blind 110 CD34+ cells DC, HF IM, IC 2014 (29)
NCT01508910 Randomized, controlled, blind 291 CD34+ cells CMI, RA, CHD IM 2016 (30)
NCT02425358 Randomized, controlled 104 BM-MNCs MI IC 2015 (31)
AG, angina; AMI, acute myocardial infarction; BMCs, bone marrow-derived cells; BM-MNCs, bone marrow-derived mononuclear cells; 
BM-MSCCs, bone marrow- derived mesenchymal cardiopoietic cells; BM-MSCs, bone marrow-derived mesenchymal stem cells; BM-
SCs, bone marrow-derived stem cells; CHD, coronary heart disease; CHF, congestive heart failure; CIHD, chronic ischemic heart disease; 
CIHF, chronic ischemic heart failure; CILVD, chronic ischemic left ventricular dysfunction; CMI, chronic myocardial ischemia; CSCs, cardiac 
stem cells; DC, dilated cardiomyopathy; G-CSF, granulocyte colony stimulating factor; HF, heart failure; IC, intracoronary; ICP, ischemic 
cardiomyopathy; IM, intramyocardial; LVD, left ventricular dysfunction; MI, myocardial infarction; MSCs, mesenchymal stem cells; RA, 
refractory angina; TEC, trans-endocardial; WJ-MSCs, umbilical Wharton's jelly-derived mesenchymal stem cell. Detailed information about 
the clinical trials are available on the web site http://clinicaltrials.gov/.
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Table 2 Ongoing NIH clinical trials with a number of coronary heart disease patients >50
NIH registration 
number
Status
No. of patients 
enrolled/to enroll
Cell type Condition
Delivery 
route
Phase
NCT00950274 Completed 81 CD133+ cells MI, CHD IM III
NCT00979758 Recruiting participants 100 BM-MNCs + atorvastatin MI IC II
NCT01458405 Active, not recruiting 134 CSpCs MI IC I and II
NCT01652209 Recruiting 135 MSCs AMI BTC III
NCT01720888 Active, not recruiting 80 BM-MSCs IDC IC II
NCT01727063 Unknown 200 BMCs IHD, CHD, AG IM II and III
NCT01748383 Unknown 85 BMCs AMI IC II
NCT01758406 Recruiting 50 BMCs HF IC II
NCT01768702 Active, not recruiting 240 BM-MSCs (C3BS-CQR- 1) IHF IM III
NCT01781390 Active, not recruiting 105 MPCs AMI IC II
NCT02022514 Recruiting participants 66 BM-MNCs CA IC II and III
NCT02059512 Active, not recruiting 100 BMCs IHD IM NP
NCT02248532 Recruiting participants 80 CD34+ cells HF, DC IM II and III
NCT02277613 Recruiting participants 90 BM-SCs HA IC II
NCT02323477 Recruiting 79 UC-MSCs MI IM I and II
NCT02438306 Recruiting participants 250 BM-MNCs HF TEC III
NCT02438306 Recruiting 250 BMCs HF TEC III
NCT02439398 Active, not recruiting 55 CSCs AMI IC I and II
NCT02462330 Recruiting participants 90 BM-MSCs CMI IM II
NCT02504437 Not yet recruiting 200 BM-MSCs MI, AMI, ICP IM I and II
NCT02666391 Not yet recruiting 64 UC-MSCs AMI, MI, ICP IC I and II
NCT02673164 Not yet open for participant 
recruitment
138 AdSCs HF IM II
NCT02962661 Not yet recruiting 72 BM-MSCs HD IV, TEC I
NCT03092284 Recruiting 81 AdSCs IHD, HF IM II
NCT03180450 Not yet recruiting 60 UC-MSCs HF IV I
AdSCs, adipose tissue-derived stem cells; AG, angina; AMI, acute myocardial infarction; BMCs, bone marrow-derived cells; BM-MNCs, 
bone marrow-derived mononuclear cells; BM-MSCs, bone marrow- derived mesenchymal stem cells; BM-SCs, bone marrow-derived stem 
cells; BTC, balloon tipped catheter; CA, coronary atherosclerosis; CHD, coronary heart disease; CMI, chronic myocardial ischemia; CSCs, 
cardiac stem cells; CSpCs, cardiosphere-derived cells; DC, dilated cardiomyopathy; HA, heart attack; HD, heart disease; HF, heart 
failure; IDC, ischemic dilated cardiomyopathy; IHD, ischemic heart disease; IHF, ischemic heart failure; IC, intracoronary; ICP, ischemic 
cardiomyopathy; IM, intramyocardial; IV, intravenous; MI, myocardial infarction; MPCs, mesenchymal precursor cells; NP, not provided; 
TEC, trans-endocardial; UC-MSCs, umbilical cord mesenchymal stem cell. Detailed information about the clinical trials are available on the 
web site http://clinicaltrials.gov/.
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of eNOS-overexpressing BM-MSCs and HGF gene-
engineered skeletal myoblasts significantly improved 
the repair and the functional recovery of the infarcted 
hearts (56,57). Interestingly, epigenetics has been clearly 
demonstrated to participate to the pro-fibrotic response of 
injured myocardium (58).
Several in vivo and in vitro studies demonstrated the 
role of miRNAs, in promoting cardiac muscle repair by 
stimulating cardiomyocyte proliferation and differentiation 
(59-61). In particular, miR-17-92, miR-23b, miR-199a, 
miR-204, miR-410, miR-495, miR-548c, miR-590, 
and miR-1825 can activate cardiomyocyte proliferation 
(59,60,62). Moreover, the inhibition of miRNA-23a 
and miRNA-92a expression reduced apoptotic death of 
rat cardiomyocytes after MI (63). Recent therapeutic 
approaches on MI explored also the use of exosomes to 
promote the repair of infarcted myocardium.
Exosomes are small endosomal membrane-bound 
vesicles secreted by cells for exchanging proteins, mRNAs 
and miRNAs. As reported in preclinical studies, exosomes 
from cardiac cells, MSCs and stem cells can be effective 
in the functional recovery of cardiac tissue from MI (64-
67). Another very promising approach is based on the 
delivery of pro-repair factors, such as neuregulin, into 
infarcted hearts using biodegradable microparticles (68,69). 
These microparticles can escape the immune system and 
constantly release the active compound for 12 weeks, until 
they degrade. Additionally, a very interesting research led 
to the development of a spraying system for a mini-invasive 
application of platelet fibrin gel on the surface of infarcted 
mouse hearts. The layered polymerizable biomaterial patch 
attenuated LV remodeling, reduced cardiomyocyte death 
and stimulated myocardial repair, thus ameliorating heart 
function (70). However, powerful methods to monitor the 
effect of cell therapy are also needed (71).
Conclusions
The clinical use of cell therapy in CHD has not reached 
a mature stage yet, where defined and standardized 
procedures are available. A consensus on cell types, number 
of cells to implant, delivery routes, transplantation timing 
is still lacking, and the number of variables to account 
for is huge. Moreover, despite the increasing amount of 
data resulting from all the preclinical and clinical studies 
realized so far, it is difficult to compare different studies 
and to extract conclusive information from them, because 
of the differences in the strategies adopted in the studies. 
Neuregulin-1
ErbB2
RAS
RAF
MEK
ERK1
Heart repair
Cardiomyocyte
proliferation
Cardiomyocyte proliferation
Collagen patch
Follistatin-Like-Protein 1
MiRNA overexpression
miR-204
miR-590
miR-199a
miR-548c
miR-410
miR-1825
miR-495
miR-17-92
miR-23b
Figure 1 Novel strategies for possible cardiac repair. The figure represents three novel approaches under investigation for repairing 
infarcted myocardium: overexpression of miRNAs; transplantation of a collagen patch loaded with follistatin-like protein 1; delivery of the 
pro-repair factor neuregulin-1.
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Nevertheless, an important point to underline is that 
autologous cell therapy is safe, and successful results have 
been collected anyway by different groups. The potential 
benefits of an effective cell therapy in CHD are so 
important that even if its efficacy has been, so far, variable 
and limited, it is still very worthwhile to invest in this field.
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